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012.03.0Abstract Cystatin-C (CYS-C) has emerged as a highly sensitive marker of even a mildly impaired
glomerular ﬁltration rate. Experimental studies have suggested that its inhibitory effects on cysteine
protease may help to prevent plaque destabilisation. We aimed to evaluate the predictive value of
CYS-C level for major adverse cardiac events (MACE) including mortality and morbidity during
the hospital stay and 3-month follow-up period.
Methods: Seventy-ﬁve patients were hospitalised for acute coronary syndrome (ACS). Another
control group consisted of patients who were presented with chest pain but no evidence of ischaemic
heart disease documented by laboratory markers and angiography. Serum CYS-C levels were mea-
sured during the ﬁrst 24 h of admission. Patients with an abnormal creatinine-derived glomerular
ﬁltration rate (GFR) were excluded. Coronary angiography was performed for the entire study pop-
ulation.
Results: In group I, the mean CYS-C was 1.836 ± 0.782 mg/l vs. 0.991 ± 0.163 mg/l in the control
group (P< 0.000). Cystatin-C showed a moderate correlation with total cholesterol in group I
(r= 0.5) and with LDL (r= 0.367, P< 0.01). CYS-C showed a moderate positive correlation with
the number of diseased vessels (r= 0.419, P< 0.01) and a moderate signiﬁcant positive correlation
with Killip classiﬁcation (r= 0.349). Smoking was the only predictor associated with a high CYS-C
level in the multivariate regression analysis (P= 0.033). CYS-C was an independent predictor of
MACE and heart failure complications either in-hospital or during follow-up (P< 0.05).
Conclusions: CYS-C could be a useful marker for diagnosing coronary arteriosclerosis. An elevated
CYS-C in patients with ACS is an independent predictor of MACE either in-hospital or during fol-
low-up.
ª 2012 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.100 5012070.
l.com (O. Tayeh).
tian Society of Cardiology.
g by Elsevier
ardiology. Production and hosting by Elsevier B.V. All rights reserved.
02
88 O. Tayeh et al.1. Introduction
Cystatin-C (CYS-C) has emerged as a highly sensitive marker
of even a mildly impaired glomerular ﬁltration rate (GFR).
Serum creatinine, an accepted marker of GFR, is limited by
multiple factors including age, gender, muscle mass, physical
activity and diet.1 CYS-C is freely ﬁltered by the glomerulus
and is not secreted or reabsorbed by the tubular epithelial cells
of kidneys because of its small size of 13 kilo Daltons (kDa).
CYS-C is a member of the cystatin super family of endogenous
cysteine protease inhibitors and is produced by all nucleated
human cells. Notably, experimental studies have suggested
that its inhibitory effects on cysteine protease might help pre-
vent plaque destabilisation.2
Studies have demonstrated that elevated serum CYS-C is
associated with a risk of cardiovascular events in asymptom-
atic elderly subjects and patients with heart failure or in acute
coronary syndrome. However, the reasons for these associa-
tions are not fully understood.3–8
In this study, we assessed the prognostic value of CYS-C as
a predictor of major adverse cardiac events (MACE) in pa-
tients with acute coronary syndrome in regards to mortality,
heart failure, electrical or mechanical complications and the
occurrence of ischaemic events during the hospital stay and
within the three months following discharge from the hospital.
2. Methods
This was a non-randomised controlled trial that was prospec-
tively conducted on 75 patients with acute coronary syndrome
(ACS) and an equal number of controls. Patients included in
this study presented with ACS, including acute myocardial
infarction (AMI), non-ST-elevation myocardial infarction
(NSTEMI) and unstable angina according to the deﬁnition
established by the Joint European Society of Cardiology/
American College of Cardiology Committee 2007.9–13
The control group comprised of 75 patients who presented
with chest pain, which later proved to be unrelated to ischae-
mic heart disease (IHD) by ECG, laboratory tests (creatine ki-
nase myocardial band fraction CK-MB and troponin I) and
coronary angiography.
The exclusion criteria consisted of patients with neoplasia
of any organ, pregnancy, thyroid dysfunction, altered mental
status, cardiogenic shock, chronic renal failure, on haemodial-
ysis, impaired kidney function on admission, suspected aortic
dissection, old myocardial infarction (MI) within 6 months,
currently receiving corticosteroid therapy and those who re-
fused to participate.
Both groups were subjected to a complete history and thor-
ough clinical examination assessing the type of ACS, Killip
class to determine the degree of heart failure at the time of hos-
pitalisation, blood pressure and heart rate.14 Body weight (kg),
height (cm), body mass index (kg/m2) and waist circumference
(cm) were recorded on admission.
Laboratory investigation included a complete blood count,
and random blood glucose, urea and creatinine,15 total choles-
terol, high-density lipoprotein cholesterol, low-density lipopro-
tein cholesterol tests. Cardiac enzymes, including troponin I,
creatine kinase (CK), CK-MB and lactic dehydrogenase
(LDH), were measured. Laboratory tests, which were per-
formed on admission, were repeated three times on the subse-quent three days. The estimated glomerular ﬁltration rate
(GFR) (millilitres per minute per 1.73 square metres) was cal-
culated using the simpliﬁed Modiﬁcation of Diet in Renal Dis-
ease (MDRD) equation:
86:3 ðserum creatinine ½mg=dlÞ  1:154 ðage ½yearsÞ
 0:203 ð0:742 if femaleÞ16:
The estimated creatinine clearance (millilitres per minute) was
calculated using the Cochcroft–Gault equation:
ð140 age ½yearsÞ  body weight ½kg  ð0:85 if femaleÞ=ð72
 serum creatinine ½mg=dlÞ16:
Human CYS-C ELISA is a sandwich enzyme immunoassay
for the quantitative measurement of human CYS-C in serum,
plasma, cerebrospinal ﬂuid and tissue culture medium. The
surface of the wells in the microtitration plate is coated with
polyclonal, anti-human, CYS-C-speciﬁc antibody, which
agglutinates with serum CYS-C, and the concentration is
determined according to colour changes. Serum CYS-C sam-
ples were drawn within the ﬁrst 24 h of admission after at least
8 h of fasting. The normal serum CYS-C concentration refer-
ence in adult, using the nephelometric method, is 0.51–
1.21 mg/l.17–19
All populations were evaluated by transthoracic echocardi-
ography and diagnostic coronary angiography, which were
interpreted by two independent experts in the coronary inter-
ventions. Maximal medical therapy and invasive management
were given to all patients, and additional investigations per-
formed during the patient’s hospital stay were based on the
clinical decisions of the attending physician. All patients were
followed up during the hospital stay and for three months after
hospital discharge.3. Statistical analyses
The data were coded and computed on a statistical package for
Social Sciences SPSS version 17 for Windows. Continuous
variables were evaluated using the t-test and categorical vari-
ables using v2. The Pearson correlation coefﬁcient (r) was cal-
culated to examine the strength and direction of the
correlation between two variables. The correlation was weak
if r< 0.3, moderate if 0.3 < r< 0.6 and strong if r> 0.6.
A receiver operating characteristic curve (ROC) analysis was
used to determine the optimal cutoff that provided the greatest
sensitivity and speciﬁcity for the predicting variables. The
results were considered to be signiﬁcant if the area under the
curve (AUC) > 0.5 cm2 and P< 0.05. Binary logistic multi-
variate regression analysis explored how much variation in
the dependent variable could be explained by variability in
two or more independent variables. P< 0.05 was considered
to be signiﬁcant.4. Results
This study was conducted from January to October 2010. We
divided the study population into two groups. Group I in-
cluded patients with ACS, and group II included control pa-
tients. The demographic data of the studied populations are
presented in Table 1.
Cystatin-C as a predictor for major adverse cardiac events in patients with acute coronary syndrome 89CYS-C level ranged from 0.775 to 4.216 mg/l with a mean
of 1.836 ± 0.782 in group I vs. 0.666–1.660 mg/l with a mean
of 0.991 ± 0.163 mg/l in the control group (P= 0.000). All
laboratory results are shown in Table 2.
Transthoracic echocardiography showed a mean EF of
51.7 ± 11.3%, LVEDD of 5.5 ± 0.9, and LVESD of
3.7 ± 0.9 in group I vs. 62.1 ± 7.5, 4.6 ± 0.7 and 3.00 ± 0.6
in the control group, respectively. Seventy-one (94.6%) pa-
tients in group I had signiﬁcant regional wall motion abnor-
malities (RWMA), whereas there was no RWMA in the
control group. All echocardiographic ﬁndings in group I were
statistically signiﬁcant compared with the control group
(P< 0.001).
CYS-C showed a moderate positive correlation with the
number of diseased vessels (r= 0.419, P< 0.01) and a moder-
ate positive correlation with Killip classiﬁcation (r= 0.349,
P< 0.01). However, CYS-C showed a weak negative correla-
tion (r= 0.066) with peak troponin I (P> 0.05) (Tables 3
and 4). There was a weak correlation between CYS-C and
the degree of left main artery stenosis (r= 0.265, P=
0.002). Additionally, there was a moderate signiﬁcant correla-
tion to the degree of circumﬂex artery stenosis (r= 0.312) and
to diagonal branch stenosis (r= 0.517), but there was a weak
correlation in left anterior descending artery, obtuse marginal
branch and right coronary artery stenosis without any statisti-
cal signiﬁcance (P> 0.05) (Table 5).
The patients in group I were further subdivided according
to the type of acute coronary syndrome into 19 patients
(25.3%) with unstable angina, 12 patients (16%) with NSTE-
MI and 44 patients (58.6%) with STEMI. Comparing the
CYS-C level among these three groups, CYS-C level ranged
from 0.775 to 4.108 mg/l with a mean of 1.634 ± 0.992.4 mg/
l in unstable angina patients. In the NSTEMI group, it ranged
from 1.748 to 4.216 mg/l (mean 2.218 ± 0.659 mg/l), and in
the STEMI group, it ranged from 0.966 to 3.823 mg/l (mean
1.805 ± 0.705 mg/l) with no signiﬁcant difference between
these groups (P = 0.129). Additionally, we subdivided group
I into two groups according to the CYS-C level, using a cutoff
point of 1.141 mg/l; this point had the maximum sensitivity
and speciﬁcity. Subgroup A consisted of 27 patients (36%)
with a CYS-C level below 1.141 mg/l, and subgroup B con-
sisted of 48 patients (64%) with a CYS-C level aboveTable 1 Demographic data of the study population.
Group I
Range Mean ± SD
Gender (male) 39 52%
Age 22–70 50.3 ± 8.1
DMa 28 37.3%
HTNa 34 45.3%
Smoker 39 52.0%
Dyslipidaemia 51 68%
High level of LDL 46 61.3%
Low level of HDL 38 50.7%
CVSa 3 4%
Weight (kg) 60–115 78.7 ± 10.3
Height (cm) 152–190 174.7 ± 10.2
BMI (kg/m2) 19–41 25.1 ± 3.8
Waist circumference (cm) 59–106 80.6 ± 10.08
a DM: diabetes mellitus, HTN: hypertension, CVS: cerebrovascular str1.141 mg/l. We found a statistically signiﬁcant difference in
CYS-C level between subgroup B compared with subgroup
A (P< 0.01). Table 6 illustrates that patients in subgroup B
had a signiﬁcantly higher number of diseased vessels compared
with patients in subgroup A (P= 0.005). Additionally, sub-
group A showed a signiﬁcantly lower number of patients
who presented with thrombus in the culprit lesion (seven pa-
tients (25%) vs. 25 patients (52%) in subgroup B,
P= 0.028). Patients in subgroup A were only Killip class 1–
2, whereas subgroup B presented with Killip class 1–4
(P= 0.045) (Table 7). Comparing patients regarding the num-
ber and location of the lesions and CYS-C level showed no sig-
niﬁcant differences between lesion site and number between
subgroups A and B (P> 0.05) (Table 8).
According to the total incidence of MACE during hospi-
tal stay, subgroup B showed a signiﬁcantly higher incidence
of complications (43 patients (89%) vs. 18 patients (66%) in
subgroup A, P= 0.014). Mechanical complications were
signiﬁcantly higher in subgroup B compared with subgroup
A (37 patients (77%) vs. 11 patients (40%), P= 0.002).
Additionally, subgroup B had a signiﬁcantly higher inci-
dence of heart failure (30 patients (62%) vs. three patients
(11%) in subgroup A, P= 0.000). However, regarding
other complications in subgroup A, it was found that elec-
trical complications occurred in 11 patients (40%) and re-
infarction complications occurred in one patient (3.7%) vs.
27 (56%) and seven (14%) patients, respectively, in sub-
group B, with no statistically signiﬁcant differences
(P> 0.05) (Table 9).
Concerning MACE during the follow-up according to
CYS-C level, subgroup B showed a signiﬁcantly higher inci-
dence of total MACE, which occurred in 38 (92.7%), whereas
MACE occurred in 18 patients (66.7%) in subgroup A
(P= 0.006) (Table 10). Subgroup B showed a signiﬁcantly
higher percentage of total mortality (18 patients (37%)) com-
pared with subgroup A, which had no mortality (P< 0.05)
(Table 11).
In a multivariate regression analysis between the prevalence
of high CYS-C and traditional risk factors for IHD, including
hypertension (HTN), diabetes mellitus (DM), smoking and
low levels of HDL cholesterol, we found that if all risk factors
were present, the patient had a high CYS-C level. The only riskGroup II P-value
Range Mean ± SD
40 53.3% 0.875
29-69 49.09 ± 8.1 0.367
30 40.0% 0.737
33 44.0% 0.870
33 44.0% 0.327
26 34.7% 0.000
25 33.3% 0.001
9 12.0% 0.000
5 6.7% 0.467
58–97 79.5 ± 10.2 0.624
156–188 174.2 ± 8.9 0.747
20.1–34.8 25.9 ± 2.6 0.138
55–100 82.9 ± 9.9 0.160
oke.
Table 2 Laboratory investigations in groups I and II.
Group I Group II P-value
Range Mean ± SD Range Mean ± SD
RBS (mg/dl)a 85–370 158.7 ± 65.7 65–217 108.1 ± 27.2 0.000
HB (g/dl)a 11.5–16.1 13.3 ± 0.9 11.1–16.9 13.4 ± 1.4 0.195
HCT (%)a 27–47 39.9 ± 3.6 32–52 41.4 ± 6.6 0.081
Peak troponin I (IU/L) 0.01–7.00 0.7 ± 1.1 0.01-0.31 0.02 ± 0.03 0.000
CK-MB (U/L) on admissiona 7–250 51.7 ± 52.1 5–19 11.7 ± 4.1 0.000
Total cholesterol (g/dl) 120–337 209.4 ± 39.9 120–300 183.3 ± 33.3 0.000
LDL cholesterol (g/dl) 49–233 116.7 ± 36.6 45–170 92.5 ± 27.9 0.000
HDL cholesterol (g/dl) 24–99 45.05 ± 13.3 45–170 57.97 ± 14.7 0.000
Serum cystatin-C (mg/l) 0.775–4.216 1.836 ± 0.782 0.666–1.660 0.991 ± 0. 163 0.000
Creatinine (mg/dl) on admission 0.5–1.2 0.89 ± 0.12 0.58–1.3 0.87 ± 0.14 0.209
UREA (mg/dl) on admission 16–130 38.9 ± 21.07 22–56 36.6 ± 8.03 0.375
Creatinine clearance on admission (ml/min) 75–133 101.4 ± 15.5 85–142 103.8 ± 11.2 0.290
GFR (ml/min/1.73 m2) on admissiona 67.2–121 91.8 ± 13.9 82–126 93.5 ± 7.6 0.139
a RBS: random blood sugar, HB: haemoglobin, HCT: haematocrit, CK-MB: creatine kinase myocardial band fraction, GFR: glomerular
ﬁltration rate.
Table 3 Correlation of CYS-C in group I with number of
diseased vessels, peak troponin and Killip class.
Serum cystatin-C
r P-value
Number of diseased vessels 0.419 <0.001
Peak troponin I level (IU/L) 0.066 0.575
Killip class on admission 0.349 0.002
Table 5 Correlation of CYS-C with the degree of stenosis in
group I.
Serum cystatin-C
r P-value
LM stenosis (%) 0.265 0.022
LAD stenosis (%)a 0.190 0.103
D stenosis (%)a 0.517 0.000
CX stenosis (%)a 0.312 0.006
OM stenosis (%)a 0.216 0.063
RCA stenosis (%)a 0.015 0.897
a LM: left main artery, LAD: left anterior descending artery, D:
diagonal artery, CX: circumﬂex artery, OM: obtuse marginal
artery, RCA: right coronary artery.
90 O. Tayeh et al.factor that correlated signiﬁcantly to CYS-C was smoking
(P< 0.05). In contrast, in a multivariate regression analysis
between the prevalence of high CYS-C and other traditional
risk factors, including DM, HTN, smoking and high LDL cho-
lesterol, if all risk factors were present, the patient had a high
CYS-C level. The only independent risk factor was a high
LDL-cholesterol level (P< 0.01).
In a multivariate regression analysis to predict the occur-
rence of MACE in subgroup B, we found that if patients with
MACE had a high CYS-C, DM, HTN and low HDL choles-
terol, the only parameter that correlated with MACE was a
high CYS-C level (P< 0.05). Therefore, a high CYS-C isTable 4 Correlation of CYS-C in group I and the control group
clearance and GFR.
Correlation of cystatin-C
Cystatin-C in group I
r P-v
Age 0.252 0.0
Total cholesterol 0.511 0.0
LDL cholesterol 0.367 0.0
HDL cholesterol 0.06 0.6
Triglycerides 0.124 0.2
Ejection fraction % 0.241 0.0
Creatinine 0.164 0.1
Creatinine clearance 0.402 0.0
MDRD GFRa 0.536 0.0
a MDRD GFR: glomerular ﬁltration rate using the simpliﬁed Modiﬁcaan independent risk factor for MACE. Additionally, in a
multivariate regression analysis concerning the occurrence
of heart failure complications in-hospital, a high CYS-C level
was signiﬁcantly associated with the occurrence of heart
failure (P< 0.05), and a low HDL cholesterol had no
signiﬁcance.with age, lipid proﬁle, ejection fraction, creatinine, creatinine
Cystatin-C in group II
alue r P-value
29 0.360 0.002
00 0.05 0.668
01 0.02 0.868
54 0.177 0.128
90 0.093 0.427
37 0.053 0.649
61 0.165 0.157
00 0.313 0.006
00 0.330 0.004
tion of Diet in Renal Disease (MDRD) equation.
Table 6 Patient subgroups according to CYS-C level, which illustrate descriptive data in both subgroup.
Subgroup A (Mean ± SD) Subgroup B (Mean ± SD) P-value
Cystatin-C
Range 0.775–1.141 1.142–4.216
Mean ± SD 1.042 ± 0.067 2.282.5 ± 0.63 0.000
Total cholesterol 184.2 ± 32.7 223.6 ± 36.7 0.000
LDL cholesterol 98.9 ± 28.1 126.6 ± 37.3 0.001
HDL cholesterol 46.7 ± 10.5 44.1 ± 14.7 0.425
Triglyceride 156.2 ± 50.7 161.7 ± 41.7 0.611
EF %a 54.9 ± 10.6 49.9 ± 11.3 0.067
LVEDDa 5.4 ± 0.6 5.5 ± 1.1 0.368
LVESDa 3.6 ± 0.8 3.7 ± 1.1 0.505
Number of diseased vessels 1.7 ± 0.775 2.2 ± 0.8 0.005
Thrombus in the culprit vessel 7 (25.7%) 25 (52.1%) 0.028
a EF: ejection fraction, LVEDD: left ventricular end-diastolic diameter, LVESD: left ventricular end-systolic diameter.
Table 7 Killip classiﬁcation in subgroups A and B.
Killip class on admission P-value
Class 1 Class 2 Class 3 Class 4
Subgroup A 18 66.7% 9 33.3% 0 0% 0 0% 0.045
Subgroup B 17 35.4% 26 54.2% 4 8.3% 1 2.1%
Cystatin-C as a predictor for major adverse cardiac events in patients with acute coronary syndrome 91A receiver operator characteristic (ROC) curve was used to
determine the sensitivity and speciﬁcity for predicting the in-
hospital occurrence of MACE. The CYS-C sensitivity was
85.2% and speciﬁcity 71.4% at a serum value greater than
1.041 mg/l (Fig. 1). Additionally, CYS-C sensitivity was
100%, and speciﬁcity was 77.2% at a serum level greater than
1.041 mg/ml for predicting in-hospital mortality in patients
with ACS (Fig. 2).
5. Discussion
CYS-C is a cysteine protease inhibitor that is believed to play
an essential role in tissue remodelling. Low levels of cystatin-C
in atherosclerotic plaques could be a risk factor for ischaemic
events, as immunostaining of CYS-C has shown low expres-
sion of this protein in atherosclerotic plaques.20,21
Our study found a signiﬁcantly higher level of cardiac en-
zymes, CYS-C and all parameters of the lipid proﬁle, including
total cholesterol, LDL cholesterol, HDL cholesterol and tri-
glycerides, in group I compared with the control group
(P< 0.05). This result was consistent with those of SekizukaTable 8 Distribution of signiﬁcant lesions in subgroups A and B.
Lesion site and number
LM LAD CX O
One lesion One lesion Two lesions One lesion O
Subgroup A 0 0% 10 37% 1 3.7% 1 3.7% 4
Subgroup B 4 8.3% 25 52.1% 2 4.2% 8 16.7% 5
P-value 0.123 0.430 0.097 0.574 0.36 0.627et al.,22 who investigated 88 outpatients suspected of having
ischaemic heart disease. Serum CYS-C was measured within
3 months before coronary angiography, and they concluded
that CYS-C itself could possibly be used to screen for coronary
artery disease in patients with suspected coronary arterioscle-
rosis. Eriksson et al.23 have stated that high cholesterol or
LDL-cholesterol levels are risk factors of IHD, but CYS-C re-
ﬂects more precisely the presence or absence of coronary artery
disease.
Our results are also consistent with those of Luc et al.,24
who conﬁrmed the association of plasma CYS-C with the inci-
dence of myocardial infarction, coronary death and angina in
9756 patients in the case-control PRIME study during the 5-
year follow-up. In their study, creatinine and GFR were not
different between the cases and the controls; whereas total cho-
lesterol, LDL cholesterol and triglycerides were signiﬁcantly
higher and HDL cholesterol was lower in the experimental
group. Additionally, the prevalence of smoking, HTN and
DM was signiﬁcantly higher in these patients. In contrast,
our study showed no difference between the experimental
and control groups regarding DM, HTN and smoking. Thus,Total lesions (Mean ± SD)
M RCA
ne lesion One lesion Two lesions
14.8% 8 29.6% 2 7.4% 1.48 ± 0.72
10.4% 7 14.6% 0 0% 1.66 ± 0.75
Table 9 Incidence of in-hospital MACE in subgroups A and B.
Serum cystatin-C P-value
Subgroup A Subgroup B
Total MACE 18 66.7% 43 89.6% 0.014
Mechanical complications 11 40.7% 37 77.1% 0.002
Heart failure 3 11.1% 30 62.5% 0.000
Electrical complications 11 40.7% 27 56.3% 0.197
Re-infarction 1 3.7% 7 14.6% 0.143
Table 10 Incidence of re-hospitalisation and MACE in both subgroups during the follow-up period.
Serum cystatin-C P-value
Subgroup A Subgroup B
Total MACEa 18 66.7% 38 92.7% 0.006
Heart failure 13 48.1% 38 79.2% 0.006
Electrical complications 11 40.7% 32 66.7% 0.029
Ischaemic complications 5 18.5% 21 43.8% 0.028
Total re-hospitalisations 2 7.4% 35 72.9% 0.000
a MACE: major adverse cardiac events.
Table 11 Total survival and death either in-hospital or during the follow-up period.
Outcomes Serum cystatin-C P-value
Subgroup A Subgroup B
Total survival 27 100.0% 30 62.5% 0.000
Total mortality 0 0% 18 37.5%
Hospital mortality 0 0% 8 16.7% 0.025
Mortality during the follow-up period 0 0% 10 20.8% 0.011
Figure 1 ROC curve to predict the sensitivity and speciﬁcity for
the occurrence of in-hospital MACE. The area under the curve
was 0.686 (P= 0.031).
92 O. Tayeh et al.it is apparent that risk prediction models relying on traditional
risk factors account for only approximately half of the vari-
ability in coronary heart disease risk.22
Animal studies have shown that the balance between prote-
ase activities and their inhibitors has an important role in vas-
cular disease.25 Luc et al.24 have suggested that ischaemic
events are the consequence of a relative insufﬁciency of prote-
ase inhibitors, such as CYS-C, in relation to increased expres-
sion of matrix proteinases in inﬂammatory atherosclerotic
lesions, even if the inﬂammatory process increases serum
CYS-C expression. Increased plasma levels in subjects with
coronary ischaemic events could indicate an overexpression
of CYS-C in cells outside of the arterial wall, which could cre-
ate a balance with the decreased arterial atherosclerotic expres-
sion of CYS-C.
Koenig et al.26 demonstrated a positive association between
the incidence of coronary artery disease (CAD) and cystatin-C
in a German cohort including 1033 subjects with ischaemic
heart disease in secondary prevention of fatal and non-fatal
cardiovascular events during 33 months of follow-up. Addi-
tionally, Kilic et al.27 investigated 160 patients hospitalised
with ACS and demonstrated that the admission serum CYS-
C level was signiﬁcantly associated with future cardiovascular
complications and mortality during 12 months of follow-up.
In our study, there was no signiﬁcant difference between
serum CYS-C among ACS patients, including STEMI, NSTE-
MI or unstable angina (P> 0.05), because all patients had the
Figure 2 ROC curve to predict in-hospital mortality in patients
with ACS. The area under the curve was 0.980 (P= 0.000).
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due to an imbalance between the synthesis and degradation
of the ﬁbrous cap leading to coronary events. This result was
consistent with Akerblom et al.,28 who also concluded that
CYS-C level was not different between the types of ACS in
16,402 patients because CYS-C functions as an important
inhibitor of proteases and a decrease in atherosclerotic plaques
could have a role in the onset of ischaemic events.20
CYS-C is not only a parameter that measures kidney func-
tion, but it is also an independent cardiovascular risk factor.
Mild or severe chronic renal insufﬁciency is associated with
atherosclerosis and CYS-C is recognised as an accurate endog-
enous marker of the glomerular ﬁltration rate that is probably
superior to creatinine.29–31 In our study, the higher CYS-C le-
vel in group I compared with the controls was not due to a de-
crease in GFR, as patients with renal impairment were
excluded from the study. Additionally, Luc et al.24 concluded
that a decreased glomerular ﬁltration rate would not justify
the higher CYS-C levels in patients with ACS compared with
the controls.24,32,33 Furthermore, Koening et al.26 noted that
CYS-C, independent of creatinine level or GFR, was associ-
ated with the risk of future coronary vascular disease in pa-
tients with CAD.
Our results showed that the CYS-C level tended to increase
as the number of diseased arteries increased. This result was
consistent with Sekizuka et al.,22 who concluded that the
CYS-C level tended to increase as the number of diseased
arteries increased. Nicholls et al.34 showed in their study that
the association between CYS-C and CAD severity was inde-
pendent of traditional risk factors, including diabetes, which
is known to be a strong predictor of atherosclerotic burden.
In our results, we failed to demonstrate an association be-
tween serum CYS-C and the number of signiﬁcant stenoses
in coronary vessels. These results were consistent with those
of Eriksson et al.,23 who failed to demonstrate in young survi-
vors of myocardial infarction an association between serum
CYS-C and the number of stenoses in the diseased vessels.
Plasma CYS-C value may have a greater capacity to stratify
patients at a high risk of cardiovascular complications during
the ﬁrst hours of hospitalisation compared with other methods
of assessing renal function.26 We found that an elevated CYS-
C level was associated with a poorer cardiovascular prognosis.
Nevertheless, our study patients had a normal glomerular ﬁl-
tration rate. When the patients were divided into two groups
(CYS-C < 1.141 mg/l or P 1.141 mg/l), the incidence of
MACE either in-hospital or during follow-up was signiﬁcantly
higher in patients with a high CYS-C, in addition to a worsen-
ing of Killip class on admission. Our results showed that a high
serum CYS-C level was a risk factor for MACE or heart fail-
ure independent of traditional risk factors, such as low HDL
cholesterol. These results are consistent with those of Garcı´a
Acun˜a et al.,33 who indicated that an elevated serum CYS-C
level predicted the development of heart failure, myocardial
infarction and cardiovascular death in 203 patients hospita-
lised with high-risk ACS, independent of other classic risk fac-
tors either in-hospital or during a 6-month follow-up period.
Sarnak et al.6 observed that when patients were divided
according to serum CYS-C, there were no signiﬁcant differ-
ences in traditional risk factors, such as diabetes mellitus and
disorders of lipid metabolism, which possibly accelerate the
progression of arteriosclerosis. Jernberg et al.7 claimed that
serum CYS-C was independently associated with mortality in726 NSTEMI population, but not with a risk of subsequent
MI. Kilic et al.27 proposed that in all of the study groups,
including STEMI, NSTEMI and unstable angina, serum
CYS-C was signiﬁcantly higher in patients with MACE com-
pared with patients without MACE. Additionally, Moran
et al.35 concluded that CYS-C can be a marker of heart failure,
and its combination with N-terminal pro-B-type natriuretic
peptide (Nt–Pro-BNP) was a better marker than CYS-C alone
for predicting cardiovascular mortality, especially in elderly
patients with heart failure.36,37
Shlipak et al.3 demonstrated that an elevated serum CYS-C
in 279 patients was associated with an increased risk of death,
cardiovascular complications and incidence of heart failure in
outpatients with chronic coronary disease. In this study,
although appropriate invasive management and maximal med-
ical therapy were given to all patients, the occurrence of
MACE among patients with higher CYS-C levels could not
be prevented. An elevated serum CYS-C level was associated
with a signiﬁcant incidence of death either in-hospital or dur-
ing follow-up. CYS-C had the greatest sensitivity in predicting
death, with 77% speciﬁcity. These data were consistent with
those of Koenig et al.,26 Jernberg et al.,7 Garcı´a Acun˜a
et al.,33 and Keller et al.,8 who reported the prognostic value
of CYS-C in predicting death in predominately male patients
with stable CAD or ACS in a cohort of the Athero Gene study.
Akerblom et al.28 concluded that the CYS-C level contributes
independently in predicting the risk of cardiovascular death or
MI in NSTEMI and showed no difference in all types of ACS.
6. Conclusions
Elevated serum CYS-C in the ﬁrst few hours of hospitalisation
for ACS is an independent predictor of MACE, especially of
94 O. Tayeh et al.heart failure, either in-hospital or during follow-up. High total
cholesterol or LDL cholesterol and low HDL cholesterol are
risk factors of IHD, but CYS-C could be a useful marker for
diagnosing coronary arteriosclerosis. CYS-C was associated
with the risk of future coronary vascular disease in patients
with CHD, independent of serum creatinine or GFR. Serum
CYS-C tended to increase as the number of diseased arteries
increased.7. Study limitations
The small sample size and the relatively short period of follow-
up are the main limitations of this study. We aimed to investi-
gate the role of CYS-C in ACS, so we excluded patients with
renal impairment, although several studies have considered re-
nal impairment as a risk factor for MACE. Further studies are
needed to conﬁrm the efﬁcacy of CYS-C for predicting adverse
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